Pharmacokinetics of vinorelbine in man. 1992

P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
Département de Pharmacologie et Toxicologie, Hôpital du Cluzeau, C.H.R.U. Dupuytren, Limoges, France.

The pharmacokinetics of vinorelbine has been investigated by a new HPLC method in 8 cancer patients receiving 8 weekly doses (30 mg.m-2) administered by brief infusion (15 min). The plasma concentration-time curves showed a tri-exponential decay with a long terminal half-life (44.7 h) and a high volume of distribution (Vz = 75.61.kg-1). The concentrations after the 8th infusion were significantly lower than after the 1st infusion, but without significant modification of CL (1.28 l.h-1.kg-1) or AUC (0.80 mg.l-1.h). The pharmacokinetic parameters exhibited wide interindividual variations. The results are consistent with those of previous RIA studies, although the HPLC method appears to be more specific and more precise.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077235 Vinorelbine A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. 5'-Nor-anhydrovinblastine,KW 2307,KW-2307,Navelbine,Vinorelbine Tartrate,5' Nor anhydrovinblastine,KW2307
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014747 Vinblastine Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) Vincaleukoblastine,Cellblastin,Lemblastine,Velban,Velbe,Vinblastin Hexal,Vinblastina Lilly,Vinblastine Sulfate,Vinblastinsulfat-Gry,Sulfate, Vinblastine

Related Publications

P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
September 1996, Clinical pharmacokinetics,
P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
October 1994, Seminars in oncology,
P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
August 2019, Cancer chemotherapy and pharmacology,
P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
January 1996, Clinical pharmacology and therapeutics,
P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
January 1993, Cancer chemotherapy and pharmacology,
P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
June 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
December 1992, Journal of clinical pharmacology,
P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
January 1980, The Journal of international medical research,
P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
January 2009, The Journal of pharmacology and experimental therapeutics,
P Marquet, and G Lachatre, and J Debord, and B Eichler, and F Bonnaud, and G Nicot
January 1971, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!